Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Kidswell Bio Corporation (4584.T)
Tokyo, JP
Kidswell Bio Corporation, headquartered in Tokyo, Japan, specializes in the development of pharmaceutical treatments for rare and complex diseases. The company, which was founded in 2001 and operated as Gene Techno Science Co.,Ltd. until rebranding in July 2021, maintains a robust pipeline of therapeutic candidates. This includes GND-004, designed for both ophthalmic conditions and oncology, and GND-007, aimed at immunological disorders. Their portfolio also features a range of antibodies being developed for cancer therapies. Further expanding its research, the GBS series encompasses GBS-001, GBS-004, and GBS-010 for oncology; GBS-005 for immunological diseases; GBS-007 and GBS-012 for eye-related ailments; GBS-008 for infectious diseases; and GBS-011 for renal conditions. Additionally, Kidswell Bio is progressing GCT-101 for alveolar clefts, GCT-102 for congenital isolated hypoganglionosis, alongside other investigational products addressing ophthalmologic disorders, cerebral palsy, peripheral nerve palsy, fractures, and spinal cord injuries.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.99% | -14.47% | -22.00% | -29.86% | -20.08% | -8.02% | +25.00% | -17.02% | -54.33% | -75.08% | -44.33% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+29.7% ★ Q1'26: -23.2% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-1,530.8% Q1'26: -239.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-13.8% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-2.1% Q1'26: -14.2% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-15.2% ★ Q1'26: -95.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+20.5% Q1'26: +16.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-18.44× Q1'26: -2.86× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
Mar 2028 1 Rev. Ana. 1 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.59B
est.
|
1.08B
est.
|
1.13B
est.
|
1.07B
est.
|
1.08B
est: 1.11B (-3.3%)
|
996.54M
est: 1.26B (-21.1%)
|
1.57B
est: 2.64B (-40.6%)
|
2.78B
est: 2.78B (+0.0%)
|
2.43B
est: 2.70B (-9.8%)
|
5.08B
est: 3.62B (+40.2%)
|
4.31B
4.31B – 4.31B
+18.9% YoY
|
4.93B
4.93B – 4.93B
+14.3% YoY
|
5.62B
5.62B – 5.62B
+14.0% YoY
|
5.84B
5.84B – 5.84B
+4.0% YoY
|
| EBITDA |
-665.87M
est.
|
-452.29M
est.
|
-473.23M
est.
|
-447.05M
est.
|
-7.31B
est: -466.53M (-1,466.6%)
|
-983.00M
est: -528.92M (-85.8%)
|
-531.89M
est: -1.11B (+51.9%)
|
-620.45M
est: -1.16B (+46.6%)
|
-1.38B
est: -1.13B (-22.3%)
|
116.26M
est: -817.93M (+114.2%)
|
-972.76M
-972.76M – -972.76M
-18.9% YoY
|
-1.11B
-1.11B – -1.11B
-14.3% YoY
|
-1.27B
-1.27B – -1.27B
-14.0% YoY
|
-1.32B
-1.32B – -1.32B
-4.0% YoY
|
| EBIT |
-666.93M
est.
|
-453.01M
est.
|
-473.98M
est.
|
-447.77M
est.
|
-7.31B
est: -467.27M (-1,464.2%)
|
-983.99M
est: -529.77M (-85.7%)
|
-534.19M
est: -1.11B (+51.8%)
|
-621.39M
est: -1.16B (+46.6%)
|
-1.38B
est: -1.13B (-22.2%)
|
115.36M
est: -819.67M (+114.1%)
|
-974.82M
-974.82M – -974.82M
-18.9% YoY
|
-1.11B
-1.11B – -1.11B
-14.3% YoY
|
-1.27B
-1.27B – -1.27B
-14.0% YoY
|
-1.32B
-1.32B – -1.32B
-4.0% YoY
|
| Net Income |
959.91M
est.
|
-3.22B
est.
|
-1.96B
est.
|
-2.29B
est.
|
-7.32B
est: -6.17B (-18.6%)
|
-1.00B
est: -1.80B (+44.4%)
|
-550.86M
est: -939.66M (+41.4%)
|
-657.43M
est: -842.46M (+22.0%)
|
-1.42B
est: 28.35M (-5,115.8%)
|
-21.14M
est: -97.59M (+78.3%)
|
502.60M
502.60M – 502.60M
+615.0% YoY
|
941.76M
941.76M – 941.76M
+87.4% YoY
|
1.44B
1.44B – 1.44B
+53.4% YoY
|
1.60B
1.60B – 1.60B
+10.5% YoY
|
| SGA |
357.78M
est.
|
243.02M
est.
|
254.27M
est.
|
240.21M
est.
|
687.00M
est: 250.67M (+174.1%)
|
883.00M
est: 284.20M (+210.7%)
|
101.90M
est: 594.16M (-82.8%)
|
182.93M
est: 624.65M (-70.7%)
|
163.96M
est: 606.65M (-73.0%)
|
207.15M
est: 257.46M (-19.5%)
|
306.20M
306.20M – 306.20M
+18.9% YoY
|
349.89M
349.89M – 349.89M
+14.3% YoY
|
398.91M
398.91M – 398.91M
+14.0% YoY
|
414.97M
414.97M – 414.97M
+4.0% YoY
|
| EPS |
23.70
est.
|
-79.55
est.
|
-48.33
est.
|
-56.60
est.
|
-264.64
est: -152.25 (-73.8%)
|
-34.79
est: -44.50 (+21.8%)
|
-17.86
est: -23.20 (+23.0%)
|
-20.77
est: -20.80 (+0.1%)
|
-40.23
est: 0.70 (-5,847.1%)
|
-0.52
est: -2.00 (+74.0%)
|
10.30
10.30 – 10.30
+615.0% YoY
|
19.30
19.30 – 19.30
+87.4% YoY
|
29.60
29.60 – 29.60
+53.4% YoY
|
32.70
32.70 – 32.70
+10.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 3/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 3/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 3/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings history not available.
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis International Small Cap Equity ETF AVDS | 0.00% | 186.87 | 0.30% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Masayuki Kawakami | Chief Development Officer | — | — |
| Munechika Sakabe | Executive Officer, Head of Pharmaceuticals Division & Chief Manufacturing Officer | — | — |
| Shinya Kurebayashi | President, Chief Executive Officer & Representative Director | — | — |
| Yasuyuki Mitani | Chief Scientific Officer & Director | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4584.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
